Public trial registry of the CCC-Munich

Trial CLL 002 (Continuum CC5013CLL2)

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
CLL 002 (Continuum CC5013CLL2)
World
Full title
:

A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of Lenalidomide (Reclimid) as maintenance therapy for patients with B-cell chronic lymphocytic leukemia following second-line therapy
Im Hämalog

World
NCT number
:
World
Responsible organization
:
3. Med 3. Med Ismaninger Str. 22 81675 München Germany Tum
Indications
Classification Code Description
- C91.1 B-CLL
Trial design
World
Phase
:
III
Status
World
Status
:
Recruitment finished
Votes
Initiiation & lock
World
Date of lock (planned / actual)
:
Unknown / Unknown
Therapy
World
Therapy
:

Chemo,Sonstige

Participants
Function Prename Surname Organization
World Responsible contact Christian Bogner Keine Organisationseinheit angegeben Magnifier